Karyopharm Therapeutics Inc. (NASDAQ: KPTI) today announced the presentation of four posters highlighting clinical data from the ongoing Phase 1b/2 ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

Corporate News FDA Hot Corp. News Hot FDA News Management Comments

Karyopharm Therapeutics (KPTI) Reports Positive Phase 1/2 Eltanexor DataDecember 11, 2017 6:00 AM Karyopharm Presents Positive Selinexor Data from the Phase 1b/2 STOMP Study at the American Society of Hematology 2017 Annual MeetingDecember 10, 2017 6:00 PM